ライフサイエンスコーパス: affinity labeling

1 erved residues, Y230 and W232, important for affinity labeling.

2 Glu-68 as the only residue to participate in affinity labeling.

3 osol and nuclei using fluorogenic assays and affinity labeling.

4 ytometry, immunoblotting, enzyme assays, and affinity labeling after treatment with EGF, paclitaxel,

5 Titrating C161 of LRAT with a specific affinity labeling agent at varying pH values shows that

6 inally, 11-cis-retinyl-bromoacetate, a known affinity-labeling agent of isomerohydrolase, also blocks

7 Potent and specific chloroketone containing affinity labeling agents have been developed.

8 end, chemical probes that incorporate known affinity labeling agents have facilitated the activity-b

9 y labeled with all-trans-retinyl ester based affinity labeling agents, suggesting a retinyl ester bin

10 125I-TGF-beta1 affinity labeling analysis of cell-surface TGF-beta rece

11 Using both affinity labeling and fluorescence quenching, we have ob

12 Affinity labeling and geometric constraints ensure that

13 ty of the enzyme is exceedingly sensitive to affinity labeling and group-specific reagents directed t

14 Affinity labeling and immunochemical studies characteriz

15 Photo-affinity labeling and mutagenesis studies have identifie

16 identified Asp-23 through the procedures of affinity labeling and site-directed mutagenesis as a cat

17 er membrane protein detected by folate-based affinity labeling and with anti-mouse RFC-1 peptide anti

18 determined by surface protein biotinylation, affinity labeling, and immunoelectron microscopy studies

19 alytic features of FAAH through mutagenesis, affinity labeling, and steady-state kinetic methods.

20 cturally different antagonists including the affinity labeling antiglucocorticoid dexamethasone 21-me

21 Our synthetic receptor-mediated affinity labeling approach broadens the scope of PTM det

22 cements for His141, previously identified by affinity labeling as being in the active site.

23 and the other by a more discrete and higher affinity labeling at Trp134-Gly135.

24 Finally, the pH dependence of kinact/KI for affinity labeling by 3-BP yields a pKa value of 6.7 +/-

25 ach reverses the paradigm of ligand-directed affinity labeling by making the receptor the synthetic c

26 1965 region of domain IV, around the site of affinity labeling by the 3' end of tRNA, and the second

27 The approach of affinity labeling can be used to identify amino acid par

28 inding to analogues of substrates and ATP in affinity labeling experiments and displayed a high level

29 lop a reliable model based on the results of affinity labeling experiments that provide atomic coordi

30 Affinity labeling experiments using specific compounds w

31 Affinity labeling experiments, using either [17-3H]10 or

32 c procedure which allows for introduction of affinity labeling groups late in the synthesis of a vari

33 r of the ICE/CED-3 family is demonstrated by affinity-labeling GT1-7 extracts from apoptotic controls

34 A vitamin A containing affinity-labeling haloacetate is described which facilit

35 ilized mutagenesis, receptor chimeras, photo-affinity labeling, hydrogen-deuterium exchange, and crys

36 Affinity labeling is a powerful tool to establish spatia

37 High-affinity labeling is demonstrated by covalent attachment

38 p-amine group in the peptides to the desired affinity labeling moieties.

39 an isothiocyanate group as the electrophilic affinity labeling moiety.

40 The combined approach of photo-affinity labeling/MS analysis with site-directed mutagen

41 Affinity labeling of FAAH with a specific nucleophile re

42 This is the first identification by affinity labeling of non-reactive amino acids within the

43 These data are consistent with affinity labeling of other members of the class B G prot

44 ion spectroscopy (FCS), we demonstrated high-affinity labeling of the active receptor (R*) conformati

45 -CoA binding domain of FadR was localized by affinity labeling of the full-length protein and an amin

46 sed; displacement ligand binding studies and affinity labeling of the IGF-1R alpha subunit indicated

47 Affinity labeling of the protease activity with an irrev

48 The 125I-IGFBP-3 affinity labeling of the putative receptor and IGFBP-3-i

49 ding the previously most informative site of affinity labeling of this receptor.

50 type V TGF-beta receptor after 125I-TGF-beta affinity labeling or Trans35S-label metabolic labeling o

51 Using a modification of a highly selective affinity labeling protocol, we demonstrated that the alp

52 The affinity labeling reagent, 3'-O-(5-fluoro-2,4-dinitrophe

53 t both Arg131 and Arg303 are modified by the affinity-labeling reagent.

54 rambucil have been used as sequence-directed affinity labeling reagents to investigate the length and

55 In this article, our affinity labeling results present the first evidence tha

56 ar selectivity was observed in intact cells, affinity labeling revealed that the active caspase speci

57 rate protection to validate specificity, the affinity labeling secosteroid has identified peptides in

58 t the first report of tandem applications of affinity labeling, site-directed mutagenesis, and intera

59 ctural integrity based on Mn(2+) binding and affinity labeling stoichiometry.

60 A double affinity-labeling strategy was used to isolate dimers th

61 Affinity labeling studies revealed that, unlike the mamm

62 role of Pro-1 in the MIF-catalyzed reaction, affinity labeling studies were performed with 3-bromopyr

63 structure-activity relationship studies, and affinity labeling studies.

64 Results of affinity-labeling studies and mutational analyses provid

65 stagnalis and the results from site-directed affinity-labeling studies were used as the basis for mod

66 A recent affinity labeling study has suggested that amino acids 7

67 Affinity labeling techniques revealed that RII-transfect

68 rent work, we have developed a new probe for affinity labeling the secretin receptor through a photol

69 ect on CCK binding, stimulated signaling, or affinity labeling through a residue within the pharmacop

70 The aim of this work was to utilize affinity labeling to determine spatial approximations wi

71 Furthermore, the affinity labeling was UV-dependent and saturable, indica

72 l isomerase domain (previously identified by affinity labeling) were created, expressed, and purified

73 Mutation of C288 to glycine abolished this affinity labeling, whereas the VDR-LBD mutants C337G and

74 entification of the protein was confirmed by affinity labeling with 14CN- and isoelectrofocusing.

75 Affinity labeling with 2-(14)C-labeled bromopyruvate ind

76 Affinity labeling with [(14)C]CRIDs and affinity chromat

77 se activity was identified as cathepsin L by affinity labeling with an activity-based probe for cyste

78 Affinity labeling with biotin-VAD-fmk of all active casp

79 Likewise, affinity labeling with N-(N(alpha)-benzyloxycarbonylglut

80 racts containing active caspases followed by affinity labeling with N-(N-benzyloxycarbonylglutamyl-N-

81 ing strategy, which integrates site-directed affinity labeling with structure-activity knowledge to c

82 red membrane currents before and after photo-affinity labeling with the agonist 2'(3')-O-(4-benzoylbe